• 제목/요약/키워드: Brain Tumors

검색결과 377건 처리시간 0.032초

Enhanced CNN Model for Brain Tumor Classification

  • Kasukurthi, Aravinda;Paleti, Lakshmikanth;Brahmaiah, Madamanchi;Sree, Ch.Sudha
    • International Journal of Computer Science & Network Security
    • /
    • 제22권5호
    • /
    • pp.143-148
    • /
    • 2022
  • Brain tumor classification is an important process that allows doctors to plan treatment for patients based on the stages of the tumor. To improve classification performance, various CNN-based architectures are used for brain tumor classification. Existing methods for brain tumor segmentation suffer from overfitting and poor efficiency when dealing with large datasets. The enhanced CNN architecture proposed in this study is based on U-Net for brain tumor segmentation, RefineNet for pattern analysis, and SegNet architecture for brain tumor classification. The brain tumor benchmark dataset was used to evaluate the enhanced CNN model's efficiency. Based on the local and context information of the MRI image, the U-Net provides good segmentation. SegNet selects the most important features for classification while also reducing the trainable parameters. In the classification of brain tumors, the enhanced CNN method outperforms the existing methods. The enhanced CNN model has an accuracy of 96.85 percent, while the existing CNN with transfer learning has an accuracy of 94.82 percent.

KBUD: The Korea Brain UniGene Database

  • Jeon, Yeo-Jin;Oh, Jung-Hwa;Yang, Jin-Ok;Kim, Nam-Soon
    • Genomics & Informatics
    • /
    • 제3권3호
    • /
    • pp.86-93
    • /
    • 2005
  • Human brain EST data provide important clues for our understanding of the molecular biology associated with the function of the normal brain and the molecular pathophysiology with brain disorders. To systematically and efficiently study the function and disorders of the human brain, 45,773 human brain ESTs were collected from 27 human brain cDNA libraries, which were constructed from normal brains and brain disorders such as brain tumors, Parkinson's disease (PO) and epilepsy. An analysis of 45,773 human brain ESTs using our EST analysis pipeline resulted in 38,396 high-quality ESTs and 35,906 ESTs, which were coalesced into 8,246 unique gene clusters, showing a significant similarity to known genes in the human RefSeq, human mRNAs and UniGene database. In addition, among 8,246 gene clusters, 4,287 genes ($52\%$) were found to contain full-length cONA clones. To facilitate the extraction of useful information in collected these human brain ESTs, we developed a user-friendly interface system, the Korea Brain Unigene Database (KBUD). The KBUD web interface allows access to our human brain data through three major search modes, the BioCarta pathway, keywords and BLAST searches. Each result when viewed in KBUD offers comprehensive information concerning the analyzed human brain ESTs provided by our data as well as data linked to various other publiC databases. The user-friendly developed KBUD, the first world-wide web interface for human brain EST data with ESTs of human brain disorders as well as normal brains, will be a helpful system for developing a better understanding of the underlying mechanisms of the normal brain well as brain disorders. The KBUD system is freely accessible at http://kugi.kribb.re.kr/KU/cgi -bin/brain. pI.

Clinical application of RapidArc volumetric modulated arc therapy as a component in whole brain radiation therapy for poor prognostic, four or more multiple brain metastases

  • Lee, Seung-Heon;Lee, Kyu-Chan;Choi, Jin-Ho;Kim, Hye-Young;Lee, Seok-Ho;Sung, Ki-Hoon;Kim, Yun-Mi
    • Radiation Oncology Journal
    • /
    • 제30권2호
    • /
    • pp.53-61
    • /
    • 2012
  • Purpose: To determine feasibility of RapidArc in sequential or simultaneous integrated tumor boost in whole brain radiation therapy (WBRT) for poor prognostic patients with four or more brain metastases. Materials and Methods: Nine patients with multiple (${\geq}4$) brain metastases were analyzed. Three patients were classified as class II in recursive partitioning analysis and 6 were class III. The class III patients presented with hemiparesis, cognitive deficit, or apraxia. The ratio of tumor to whole brain volume was 0.8-7.9%. Six patients received 2-dimensional bilateral WBRT, (30 Gy/10-12 fractions), followed by sequential RapidArc tumor boost (15-30 Gy/4-10 fractions). Three patients received RapidArc WBRT with simultaneous integrated boost to tumors (48-50 Gy) in 10-20 fractions. Results: The median biologically effective dose to metastatic tumors was 68.1 $Gy_{10}$ and 67.2 $Gy_{10}$ and the median brain volume irradiated more than 100 $Gy_3$ were 1.9% (24 $cm^3$) and 0.8% (13 $cm^3$) for each group. With less than 3 minutes of treatment time, RapidArc was easily applied to the patients with poor performance status. The follow-up period was 0.3-16.5 months. Tumor responses among the 6 patients who underwent follow-up magnetic resonance imaging were partial and stable in 3 and 3, respectively. Overall survival at 6 and 12 months were 66.7% and 41.7%, respectively. The local progression-free survival at 6 and 12 months were 100% and 62.5%, respectively. Conclusion: RapidArc as a component in whole brain radiation therapy for poor prognostic, multiple brain metastases is an effective and safe modality with easy application.

전이성 뇌종양의 방사선치료 성적 (Radiation Therapy for Brain Metastases)

  • 김일한;박찬일
    • Radiation Oncology Journal
    • /
    • 제2권1호
    • /
    • pp.33-39
    • /
    • 1984
  • One hundred and twenty patients with brain metastases were seen and evaluated in the Dept. of Therapeutic Radiology, Seoul National University Hospital between 1979 and 1983. Of these, 90 Patients received whole brain irradiation with 2,000 ra4 in 1 week or 3,000 rad in 2 weeks for Palliative Purpose and 30 patients failed to complete the planned treatment. Carcinoma of the lung(44 cases), choriocarcinoma(11 cases), breast(8 cases) were common Primary tumors of 90 patients receiving planned treatment. Symptomatic subjective response was obtained in $92\%$ of Patients and meurologic functional improvement was obtained in $42\%$ of patients. Median survival was 6.4 months in patients with complete treatment an·d less than 2 months in Patients with incomplete treatment, overall survival rate at 1 year and 2 year were $26\%,\;16\%$ in Patients with complete treatment and $8\%,\;0\%$ in patients with incomplete treatment. Primary site, extent of metastases and interval from diagnosis of primary tumor to brain metastases were identified as prognostic factors.

  • PDF

Neuroendoscopy : Current and Future Perspectives

  • Shim, Kyu Won;Park, Eun Kyung;Kim, Dong-Seok;Choi, Joong-Uhn
    • Journal of Korean Neurosurgical Society
    • /
    • 제60권3호
    • /
    • pp.322-326
    • /
    • 2017
  • Neuroendoscopic surgery is performed because it causes minimal damage to normal structures, carries a lower rate of complications, and achieves excellent outcomes. Surgeons using an endoscope and related instruments can perform complex operations through very small incisions, which is especially useful for minimally invasive procedures for the brain and spine. Neuroendoscopic surgery is now performed in cases of obstructive hydrocephalus, various intraventricular lesions, hypothalamic hamartomas, craniosynostosis, skull base tumors, and spinal lesions. This review discusses the brief history of neuroendoscopy and the current state and future perspectives of endoscopic surgery.

CHEMOPREVENTIVE EFFECTS OF XANTHORRHIZOL

  • Park, Kwang-Kyun;Chung, Won-Yoon;Kim, Hee-Ok;Kim, Hee-Kyong;Park, Min-Ah;Kim, Mi-Jeong;Sohn, Joon-Hyung
    • 한국독성학회:학술대회논문집
    • /
    • 한국독성학회 2001년도 International Symposium on Signal transduction in Toxicology
    • /
    • pp.145-145
    • /
    • 2001
  • Xanthorrhizol is a sesquiterpenoid isolated from Curcuma xanthorrhiza Roxb. (Zingiberaceae) that has been traditionally used in Indonesia for dietary and medicinal purposes. In our studies to evaluate the cancer chemopreventive potential, xanthorrhizol inhibited the mutagenesis induced by reactive oxygen species in Sa;monella typhimurium TA 102 in a dose-related manner and decreased significantly the incidence and the multiplicity of skin tumors initiated by 7, 12-dimethylbenz[$\alpha$]anthracene and promoted by 12-Ο-tetradecanoylphorbol-13-acetate at 19 weeks.(omitted)

  • PDF

Surgical Outcomes of Thalamic Tumors in Children: The Importance of Diffusion Tensor Imaging, Neuro-Navigation and Intraoperative Neurophysiological Monitoring

  • Kim, Jun-Hoe;Phi, Ji Hoon;Lee, Ji Yeoun;Kim, Kyung Hyun;Park, Sung-Hye;Choi, Young Hun;Cho, Byung-Kyu;Kim, Seung-Ki
    • Brain Tumor Research and Treatment
    • /
    • 제6권2호
    • /
    • pp.60-67
    • /
    • 2018
  • Background Recently, modern technology such as diffusion tensor imaging (DTI), neuro-navigation and intraoperative neurophysiological monitoring (IOM) have been actively adopted for the treatment of thalamic tumors. We evaluated surgical outcomes and efficacy of the aforementioned technologies for the treatment of pediatric thalamic tumors. Methods We retrospectively reviewed clinical data from 37 children with thalamic tumors between 2004 and 2017. There were 44 operations (27 tumor resections, 17 biopsies). DTI was employed in 17 cases, neuro-navigation in 23 cases and IOM in 14 cases. All diagnoses were revised according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System. Progression-free survival (PFS) and overall survival (OS) rates were calculated, and relevant prognostic factors were analyzed. The median follow-up duration was 19 months. Results Fifteen cases were gross total resections (GTR), 6 subtotal resections (STR), and 6 partial resections (PR). Neurological status did not worsen after 22 tumor resections. There were statistically significant differences in terms of the extent of resection between the groups with DTI, neuro-navigation and IOM (n=12, GTR or STR=12) and the group without at least one of the three techniques (n= 15, GTR or STR=9, p=0.020). The mean PFS was $87.2{\pm}38.0$ months, and the mean OS $90.7{\pm}36.1$ months. The 5-year PFS was 37%, and the 5-year OS 47%. The histological grade ($p{\leq}0.001$) and adjuvant therapy (done vs. not done, p=0.016) were significantly related to longer PFS. The histological grade (p=0.002) and the extent of removal (GTR/STR vs. PR/biopsy, p=0.047) were significantly related to longer OS. Conclusion Maximal surgical resection was achieved with acceptable morbidity in children with thalamic tumors by employing DTI, neuro-navigation and IOM. Maximal tumor resection was a relevant clinical factor affecting OS; therefore, it should be considered the initial therapeutic option for pediatric thalamic tumors.

뇌간 신경교종(Brainstem Glioma) 환아(患兒) 경험(經驗)1예(例) (A Case of A Child with Brainstem Glioma)

  • 정재환;이진용;김덕곤
    • 대한한방소아과학회지
    • /
    • 제12권1호
    • /
    • pp.55-61
    • /
    • 1998
  • Brainstem gliomas remain an important oncologic problem in the pediatric age group. These tumors constitute between 10 and 15% of all intracranial childhood tumors and despite advanced in the diagnosis and treatment of children with brain tumors, brainstem gliomas are still almost invariably rapidly lethal. We have few of clinical records of braintumors and admission case in the oriental medical hospital, classifications of tumor, symptoms and etc, specially in the pediatrics, so we introduce a case of a 7-year-old child with brainstem glioma which is diagnosised by MRI in our hospital.

  • PDF

Expression of Cancer-Testis Antigens in Pediatric Cancers

  • Ghafouri-Fard, Soudeh
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권13호
    • /
    • pp.5149-5152
    • /
    • 2015
  • Cancer-testis antigens (CTAs) are a group of tumor-associated antigens with more than 140 members whose expression has been shown to be limited to gametogenic tissues and placenta among normal tissues. However, malignant tissues of different origins have shown aberrant and elevated expression of these antigens. Such a pattern of expression endows beneficial properties for use as cancer biomarkers as well as immunotherapeutic targets as a result of the immune-privileged status of the testes. CTAs have been shown to be expressed in pediatric brain tumors, different types of sarcomas, leukemias, and lymphomas as well as neuroblastomas. Although data regarding their expression pattern in childhood tumors are not as comprehensive as for adult tumors, it is supposed that CTA-based immunotherapeutic approaches can also be used for pediatric cancers. However, there are limited data about the objective clinical responses following immunotherapy in such patients. Here we try to review the available information.

Epithermal Neutron Flux Enhancement Using SMA in Designing a Cf-Based Neutron Beam for BNCT

  • Kim, Do-Heon;Kim, Jong-Kyung
    • 한국원자력학회:학술대회논문집
    • /
    • 한국원자력학회 1995년도 추계학술발표회논문집(2)
    • /
    • pp.937-942
    • /
    • 1995
  • Great interest has prompted Boron Neutron Capture Therapy (BNCT) as a new treatment for brain tumors. The use of $^{252}$Cf as a neutron source for BNn makes the in-hospital treatments of tumors to be possible. Newly proposed subcritical multiplying assemblies (SMA) are explored to improve relatively tow neutron fluxes of the source and construct the feasibilities of $^{252}$Cf as a neutron source. The MCNP code has been used to evaluate the effective multiplication factor of the entire system and the intensities and percentages of epithermal neutron flux at the patient-end surface of the system. The neutron beam using SMA shows the epithermal neutron flux enhancement of about 13 times as large as the beam without using SMA. It is expected that the neutron beam proposed in this research will be more effective for treatment of tumors due to the increased therapeutic neutron fluxes.

  • PDF